...
首页> 外文期刊>Journal of Photochemistry and Photobiology, B. Biology: Official Journal of the European Society for Photobiology >Benzamide porphyrins with directly conjugated and distal pyridyl or pyridinium groups substituted to the porphyrin macrocycles: Study of the photosensitising abilities as inducers of apoptosis in cancer cells under photodynamic conditions
【24h】

Benzamide porphyrins with directly conjugated and distal pyridyl or pyridinium groups substituted to the porphyrin macrocycles: Study of the photosensitising abilities as inducers of apoptosis in cancer cells under photodynamic conditions

机译:苯甲酰胺卟啉,具有直接缀合的和远端吡啶基或吡啶鎓基团取代的卟啉癌:在光动力学条件下作为癌细胞中凋亡的诱导剂的光敏能力研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Amphiphilic porphyrin photosensitisers (PSs) having combinations of directly substituted pyridyl group(s) at the meso-position of a porphyrin macrocycle, and/or indirectly linked pyridyl groups as benzamide derivatives are reported. The compounds 5,10,15,20-tetrakis-(4-pyridylbenzamide)porphyrin (A.2), 5,10,15,20-tetra[N-(pyridine-4-yl)benzamidium] porphyrin (A.3), 5-mono-(4-pyridyl)-10,15,20-tris-(4-pyridylbenzamide)porphyrin (B.2) and 5-mono-(4-methylpyridinium)-10,15,20-tris-(4-pyridiniumbenzamide)porphyrin (B.3) were synthesised. The compounds were successfully characterised through UV-Vis, Emission, H-1 NMR, and ESI-HRMS techniques. To evaluate the effect of this combination of directly conjugated and non-conjugated pyridyl/cationic pyridinium groups on the porphyrin macrocycle, the efficacy of the synthesised compounds was compared to a known standard 5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin (TMPyP). These compounds show better efficacy (IC50's ranging between 0.66 +/- 0.04 mu M to 3.71 +/- 1.01 mu M) against A549 (human epithelial adenocarcinoma lung cancer) cell line under in vitro photodynamic conditions in comparison to MDA-MB-231 (breast cancer) (IC50's ranging between 3.7 +/- 0.087 mu M to 12.1 +/- 0.12 mu M) and Pa-1 (ovarian cancer) (IC50's ranging between 17.9 +/- 0.01 mu M to 42.45 +/- 0.02 mu M) cell lines. It was found that B.3, having a pyridinium group attached to the meso-position of the macrocycle along with three distal cationic pyridinium groups, independent of the porphyrinic electron delocalisation cycle, showed better photocytotoxic efficacy (IC50 = 0.66 +/- 0.04 mu M, A549 lung cancer cell line) and higher potential to promote apoptosis and hence better efficacy as PS towards cancer photodynamic therapy (PDT). The PDT activity of B.3 was further verified and established by various biological assays, viz. Annexin V assay, cell cycle assay, and reactive oxygen species (ROS) activity assay.
机译:报道了卟啉宏循环的中间吡啶基和/或间接连接的吡啶基作为苯甲酰胺衍生物的直接取代的吡啶基组合的两亲性卟啉光囊炎(PSS)。化合物5,10,15,20-四 - (4-吡啶基苯甲酰胺)卟啉(A.2),5,10,15,20-四[N-(吡啶-4-基)苯并脒]卟啉(A.3 ),5-单 - (4-吡啶基)-10,15,20-三 - (4-吡啶疏苯胺)卟啉(B.2)和5-单 - (4-甲基吡啶)-10,15,20-三 - (4-吡啶鎓苄酰胺)合成卟啉(B.3)。通过UV-Vis,发射,H-1 NMR和ESI-HRMS技术成功地表征化合物。为了评估直接缀合和非共轭吡啶基/阳离子吡啶鎓基团在卟啉癌上的这种组合的影响,将合成化合物的功效与已知标准的5,10,15,20-四(1-甲基吡啶鎓 - 4-基)卟啉(TMPYP)。与MDA-MB-231相比(乳腺癌)(IC50的范围在3.7 +/- 0.087 mu m〜12.1 +/- 0.12 mu m)和Pa-1(卵巢癌)(IC50的范围在17.9 +/- 0.01 mu m至42.45 +/- 0.02 mu m ) 细胞系。发现B.3,具有与大循环的中间位置附着的吡啶鎓基团以及三个远端阳离子吡啶基团,与卟啉电子移植循环循环无关,表现出更好的光卵毒性功效(IC50 = 0.66 +/-0.04μm M,A549肺癌细胞系)和促进细胞凋亡的潜力较高,因此更好地用作癌症光动力治疗(PDT)。 B.3的PDT活性由各种生物测定,VIZ进一步验证和建立。膜蛋白V测定,细胞周期测定和反应性氧(ROS)活性测定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号